Tag: Nasdaq:XLO

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2025, the company granted non-qualified stock options to purchase 10,700 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsNasdaq:XLO

Hope Regional Cancer Center Earns Prestigious ACR Accreditation for Excellence in Cancer Care

REE Automotive Receives Nasdaq Minimum Bid Price Notification

Dalai Lama’s 90th: A Global Celebration of Compassion, Peace, and Wisdom

Tag: Nasdaq:XLO

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us